Esperionは、第6のANDA提出者と和解に達しました
EsperionはRenata Limitedと合意に達し、NEXLETOLまたはNEXLIZETのジェネリック製品を2040年4月19日まで市場に出さないことで合意しました。これにより特許訴訟が解決しました。
なぜ重要か. この調達は、EsperionのNEXLETOLおよびNEXLIZETに対する特許保護と市場独占権に影響を与え、その収益と競争力の位置に影響を及ぼします。
01
誰に影響するか
- 1Esperion
- と協定 →事実
02
根拠
- GGlobeNewswire public company news企業開示2026-10-07 20:00
Esperion, a company wholly-owned by ARCHIMED, today announced that it has entered into a settlement agreement with Renata Limited (along with an affiliate).
- GGlobeNewswire public company news企業開示2026-10-07 20:00
This agreement resolves the patent litigation brought by Esperion against Renata in response to Renata’s Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of NEXLETOL and NEXLIZET prior to the expiration of the applicable patents. Pursuant to…
- GGlobeNewswire public company news企業開示2026-10-07 20:00
The pending patent litigation against the remaining defendants (Aurobindo Pharma Limited (along with an affiliate); MSN Pharmaceuticals Inc. (along with an affiliate); and Sandoz Inc.) is ongoing, and there can be no assurance whether such ongoing patent litigation will allow a…